变应性支气管肺曲霉病的药物治疗现状与研究进展

Current status and research progress of drug therapy for allergic bronchopulmonary aspergillosis

变应性支气管肺曲霉病(ABPA)是由烟曲霉致敏所引起的一种气道高反应疾病。在我国, ABPA主要与哮喘合并, 常常表现为哮喘控制不良和反复出现的肺部阴影。ABPA治疗的基础是口服激素, 而口服激素的剂量与疗程、吸入激素应用的适用人群、抗真菌治疗的地位以及生物制剂治疗的潜在获益等临床问题得到了越来越多的关注。本文结合近几年有关ABPA的基础和临床研究, 对上述问题进行循证收集与整理总结, 为临床治疗提供思路。

Allergic bronchopulmonary aspergillosis(ABPA)is an inflammatory disease with airway hyperresponsiveness caused by Aspergillus fumigatus,which occurs mainly in patients with asthma and results in poor asthma control and recurrent lung shadows.Oral steroid is the fundamental therapy for treating ABPA.However,the optimizing dosage and duration of oral steroid,the target population of inhaled steroid,the value of adjunctive antifungal therapy,and the potential benefits from biologic therapy are not clarified.The current review summarizes the recent advances in the management of ABPA to provide suggestions for clinical treatment.